Mukesh Ambani led Reliance Industries Limited (RIL)'s subsidiary Reliance Strategic Business Ventures will be acquiring a majority stake in Strand Life Sciences at an initial cost of Rs 393 crore, Economic Times.
Furthermore, the company will also be investing Rs 160 crore into Strand Life Sciences by March 2023.
The RIL Arm will buy 2,28,42,654 equity shares of Strand Life Sciences for a cash consideration of Rs. 393 crore.
After the acquisition, RIL's aforementioned subsidiary will hold around 80.3 per cent stake in the company on a fully diluted basis.
In an exchange filing, RIL said, "The aforesaid investment is part of group’s digital health initiatives, to foster affordable access to world-class technology and innovation-led healthcare ecosystem in India."
It should also be noted that the acquisition required no governmental or regulatory approvals.
Before this, last year, RIL had through its retail arm also acquired online medicines ordering and delivery startup Netmeds.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.